Zwaans Bernadette M M, Nicolai Heinz G, Chancellor Michael B, Lamb Laura E
Department of Urology, William Beaumont Hospital Royal Oak, MI.
Rev Urol. 2016;18(2):57-65. doi: 10.3909/riu0700.
As diagnosis and treatment of cancer is improving, medical and social issues related to cancer survivorship are becoming more prevalent. Hemorrhagic cystitis (HC), a rare but serious disease that may affect patients after pelvic radiation or systemic chemotherapy, has significant unmet medical needs. Although no definitive treatment is currently available, various interventions are employed for HC. Effects of nonsurgical treatments for HC are of modest success and studies aiming to control radiation-induced bladder symptoms are lacking. In this review, we present current and advanced therapeutic strategies for HC to help cancer survivors deal with long-term urologic health issues.
随着癌症诊断和治疗水平的提高，与癌症幸存者相关的医学和社会问题日益普遍。出血性膀胱炎（HC）是一种罕见但严重的疾病，可能在盆腔放疗或全身化疗后影响患者，存在重大未满足的医疗需求。尽管目前尚无明确的治疗方法，但针对HC采用了各种干预措施。HC非手术治疗的效果取得了一定成功，但缺乏旨在控制放疗引起的膀胱症状的研究。在本综述中，我们介绍了HC的当前和先进治疗策略，以帮助癌症幸存者应对长期泌尿系统健康问题。
